Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,919 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, nilutamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
bevacizumab, satraplatin
Biological · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Detroit, Michigan
Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Saruparib, Placebo, Enzalutamide, Darolutamide, Abiraterone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
42
States / cities
Hot Springs, Arkansas • Springdale, Arkansas • Beverly Hills, California + 36 more
Conditions
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
Interventions
LY4257496, Standard of Care Anticancer Therapies, LY4257529
Drug · Diagnostic Test
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
16
States / cities
Duarte, California • Santa Monica, California • Stanford, California + 11 more
Conditions
Prostate Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Hormone Refractory Prostate Cancer Disease
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Active, not recruiting Not applicable Interventional

CyberKnife Dose Escalation Prostate Cancer Trial

NCT03822494
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
Interventions
CyberKnife SBRT
Radiation
Lead sponsor
Crozer-Keystone Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Neoplasms
Interventions
feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
SX-682, DTX
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
32
States / cities
Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more
Conditions
Prostatic Neoplasms
Interventions
Niraparib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Riverside, California + 20 more
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Phase I and Phase II: LAE001/prednisone + afuresertib
Drug
Lead sponsor
Laekna Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Encinitas, California • Norwich, Connecticut + 9 more
Conditions
Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer
Interventions
Darolutamide, Relugolix
Drug
Lead sponsor
Atish Choudhury, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Prostate Cancer
Interventions
microarray analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Atlanta, Georgia • Springfield, Illinois • City of Saint Peters, Missouri + 4 more
Conditions
Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Prostate Cancer
Interventions
Biopsy or prostatectomy
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Obesity, Prostate Cancer
Interventions
Weight Loss Program, Standardized educational flyer, Weight Maintenance Program
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Prostate Cancer
Interventions
dMD-002, Control
Device · Other
Lead sponsor
Mochida Medical USA, Inc.
Industry
Eligibility
40 Years to 74 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 1Phase 2 Interventional Results available

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Conditions
Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
Interventions
Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
Procedure · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Prostate Cancer
Interventions
Cabozantinib
Drug
Lead sponsor
Edwin Posadas, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hormone Refractory Prostate Cancer
Interventions
AT-101, prednisone and docetaxel, placebo, prednisone and docetaxel
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more